Targeting TNF-α for the treatment of inflammatory bowel disease

Author： Billiet Thomas   Rutgeerts Paul   Ferrante Marc   Van Assche Gert   Vermeire Séverine  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.14, Iss.1, 2014-01, pp. : 75-101

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adalimumab – a new TNF-α antibody for treatment of inflammatory joint disease

By Machold Klaus P   Smolen Josef S  

Expert Opinion on Biological Therapy, Vol. 3, Iss. 2, 2003-04 ,pp. : 351-360

Informa Healthcare

Access to resources Recommend Favorite

Alicaforsen therapy in inflammatory bowel disease

By Barish Charles F  

Expert Opinion on Biological Therapy, Vol. 5, Iss. 10, 2005-10 ,pp. : 1387-1391

Informa Healthcare

Access to resources Recommend Favorite

BDNF and TNF-α polymorphisms in memory

By Yogeetha B.   Haupt L.   McKenzie K.   Sutherland H.   Okolicsyani R.   Lea R.   Maher B.   Chan R.   Shum D.   Griffiths L.  

Molecular Biology Reports, Vol. 40, Iss. 9, 2013-09 ,pp. : 5483-5490

Springer Publishing Company

Access to resources Recommend Favorite

Anti-TNF-α agents in the treatment of psoriatic arthritis

By Brandt Jan   Braun Jürgen  

Expert Opinion on Biological Therapy, Vol. 6, Iss. 2, 2006-02 ,pp. : 99-107

Informa Healthcare

Access to resources Recommend Favorite

Depleted mucosal antioxidant defences in inflammatory bowel disease

By Buffinton G.D.   Doe W.F.  

Free Radical Biology and Medicine, Vol. 19, Iss. 6, 1995-12 ,pp. : 911-918

Elsevier

Access to resources Recommend Favorite